New cocktail of drugs tested for tough prostate cancer
NCT ID NCT02913196
First seen May 08, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This early-phase study tested a combination of four drugs (apalutamide, abiraterone, docetaxel, and prednisone) in 16 men with metastatic castrate-resistant prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose of apalutamide when given with the other drugs. Researchers also tracked PSA levels and cancer progression. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GU Research Network/Urology Cancer Center
Omaha, Nebraska, 68130, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.